Lupin received five observations from the US health regulator after inspection of its Vizag facility in Andhra Pradesh. The inspection of company's Vizag API manufacturing facility by the United States Food and Drug Administration (USFDA) has been completed, Lupin said in a filing to BSE.
Feedback
LUPIN 
Reputation: 649 • Jan 20, 2020 1:52 PM
Vote
Comment
Share
NSE:LUPIN price when posted: 766.65